APA (7th ed.) Citation

AM, S., & SD, W. (2024). Cardiovascular and renal benefits of sodium-glucose cotransporter-2 inhibitors: Pathophysiologic mechanisms and clinical evidence. Minerva cardiology and angiology. https://doi.org/10.23736/S2724-5683.24.06600-6

Chicago Style (17th ed.) Citation

AM, Small, and Wiviott SD. "Cardiovascular and Renal Benefits of Sodium-glucose Cotransporter-2 Inhibitors: Pathophysiologic Mechanisms and Clinical Evidence." Minerva Cardiology and Angiology 2024. https://doi.org/10.23736/S2724-5683.24.06600-6.

MLA (9th ed.) Citation

AM, Small, and Wiviott SD. "Cardiovascular and Renal Benefits of Sodium-glucose Cotransporter-2 Inhibitors: Pathophysiologic Mechanisms and Clinical Evidence." Minerva Cardiology and Angiology, 2024, https://doi.org/10.23736/S2724-5683.24.06600-6.